

How Immunotherapy Unmasks Invisible Lung Cancer

Written by The Life Science Feed Editorial Team · Published 29 May 2026 · Edited by James Carter

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Reck M et al. KEYNOTE-024: pembrolizumab vs chemotherapy in PD-L1 high NSCLC. N Engl J Med. 2016;375:1823-1833
2. Mok TSK et al. IMpower110: atezolizumab vs chemotherapy in PD-L1 selected NSCLC. J Clin Oncol. 2021;39:2235-2245
3. Brahmer J et al. Nivolumab vs docetaxel in advanced squamous-cell NSCLC. N Engl J Med. 2015;373:123-135
4. Herbst RS et al. KEYNOTE-010: pembrolizumab vs docetaxel in PD-L1 positive NSCLC. Lancet. 2016;387:1540-1550
5. Paz-Ares L et al. KEYNOTE-407: pembrolizumab plus chemotherapy in squamous NSCLC. N Engl J Med. 2018;379:2040-2051

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com